Skip to content

Registration study of intravenous thrombolysis with recombinant human TNK tissue plasminogen activator for injection in primary hospitals for acute ischemic stroke

Registration study of intravenous thrombolysis with recombinant human TNK tissue plasminogen activator for injection in primary hospitals for acute ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100539
Enrollment
Unknown
Registered
2025-04-10
Start date
2024-03-23
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Sponsors

The First Affiliated Hospital,Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Over 18 years old; 2.AIS patients who, within 4.5 hours of onset, meet the criteria for intravenous thrombolytic therapy and are treated with intravenous thrombolysis using rhTNK-tPA or alteplase. 3.Repeat CT or brain MRI results confirm acute cerebral infarction. 4.Complete a 90-day follow-up and sign an informed consent form;

Exclusion criteria

Exclusion criteria: 1.Already participated in other clinical studies with intervention measures; 2.Lost to follow-up; 3.Incomplete clinical data;

Design outcomes

Primary

MeasureTime frame
Symptomatic intracranial hemorrhage within 24 hours after onset;The proportion of patients with a modified Rankin Scale (mRS) score of 0-1 at 90 days;NIHSS score 24 hours after onset;

Secondary

MeasureTime frame
Symptomatic intracranial hemorrhage within 90 days after onset;Symptomatic intracranial hemorrhage (PH2 type)within 90 days after onset;intracranial hemorrhage within 90 days after onset;90-day mortality and recurrence rate of cerebral infarction;90-day adverse reactions or serious adverse reactions;The proportion of patients with a modified Rankin Scale (mRS) score of 0-2 at 90 days;distribution of 90-day mRS;Key thrombolysis time indicators;

Countries

China

Contacts

Public ContactJingjing Li

The First Affiliated Hospital,Sun Yat-sen University

lijj7@mail.sysu.edu.cn+86 20 87332200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026